230
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro

, , &
Pages 256-263 | Received 27 Feb 2011, Accepted 01 Apr 2011, Published online: 27 May 2011

Reference

  • Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408, 307–310.
  • Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303, 1010–1014.
  • Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8, 275–283.
  • Kruse JP, Gu W. SnapShot: p53 posttranslational modifications. Cell 2008, 133, 930–30.e1.
  • Zhang Y, Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001, 292, 1910–1915.
  • Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408, 377–381.
  • Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009, 9, 862–873.
  • Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007, 12, 303–312.
  • Ryu SY, Kim K, Lee WS, Kwon HC, Lee KH, Kim CM, Kang SB. Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines. J Gynecol Oncol 2009, 20, 48–54.
  • Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002, 8, 282–288.
  • Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844–848.
  • Fimia GM, Sassone-Corsi P. Cyclic AMP signalling. J Cell Sci 2001, 114, 1971–1972.
  • Murray AJ. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal 2008, 1, re4.
  • Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai) 2008, 40, 651–662.
  • Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 1995, 374, 421–424.
  • Amsterdam A, Keren-Tal I, Aharoni D. Cross-talk between cAMP and p53-generated signals in induction of differentiation and apoptosis in steroidogenic granulosa cells. Steroids 1996, 61, 252–256.
  • Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999, 274, 36031–36034.
  • Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG, Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2009, 33, 462–471.
  • Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10, 1321–1328.
  • Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P. Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis 2010, 15, 196–203.
  • Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002, 21, 6236–6245.
  • Tiwari S, Felekkis K, Moon EY, Flies A, Sherr DH, Lerner A. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood 2004, 103, 2661–2667.
  • Krakstad C, Christensen AE, Døskeland SO. cAMP protects neutrophils against TNF-alpha-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). J Leukoc Biol 2004, 76, 641–647.
  • Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445, 661–665.
  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266, 807–810.
  • Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996, 122, 360–365.
  • Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, Zehbe I. The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003, 21, 307–312.
  • Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18, 1660–1672.
  • Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53, 2231–2234.
  • Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999, 3, 579–591.
  • Kruse JP, Gu W. Modes of p53 regulation. Cell 2009, 137, 609–622.
  • Martin MC, Dransfield I, Haslett C, Rossi AG. Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. J Biol Chem 2001, 276, 45041–45050.
  • Lømo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol 1995, 154, 1634–1643.
  • Hosokawa K, Aharoni D, Dantes A, Shaulian E, Schere-Levy C, Atzmon R, Kotsuji F, Oren M, Vlodavsky I, Amsterdam A. Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Endocrinology 1998, 139, 4688–4700.
  • García-Bermejo L, Pérez C, Vilaboa NE, de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci 1998, 111 (Pt 5), 637–644.
  • von Knethen A, Brüne B. Attenuation of macrophage apoptosis by the cAMP-signaling system. Mol Cell Biochem 2000, 212, 35–43.
  • Geier A, Weiss C, Beery R, Haimsohn M, Hemi R, Malik Z, Karasik A. Multiple pathways are involved in protection of MCF-7 cells against death due to protein synthesis inhibition. J Cell Physiol 1995, 163, 570–576.
  • Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med 2006, 40, 1564–1577.
  • Jun CD, Pae HO, Yoo JC, Kwak HJ, Park RK, Chung HT. Cyclic adenosine monophosphate inhibits nitric oxide-induced apoptosis in human leukemic HL-60 cells. Cell Immunol 1998, 183, 13–21.
  • Grandoch M, Bujok V, Fleckenstein D, Schmidt M, Fischer JW, Weber AA. Epac inhibits apoptosis of human leukocytes. J Leukoc Biol 2009, 86, 847–849.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.